Compare FTRE & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTRE | RGR |
|---|---|---|
| Founded | 1996 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.3M | 677.2M |
| IPO Year | 2023 | 1994 |
| Metric | FTRE | RGR |
|---|---|---|
| Price | $15.46 | $41.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $14.06 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 1.3M | 90.7K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.07% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,723,400,000.00 | $546,057,000.00 |
| Revenue This Year | N/A | $2.38 |
| Revenue Next Year | $3.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.00 | ★ 1.94 |
| 52 Week Low | $3.97 | $28.33 |
| 52 Week High | $18.67 | $48.21 |
| Indicator | FTRE | RGR |
|---|---|---|
| Relative Strength Index (RSI) | 82.48 | 44.48 |
| Support Level | $8.85 | $38.60 |
| Resistance Level | $18.26 | $44.00 |
| Average True Range (ATR) | 0.81 | 1.01 |
| MACD | 0.56 | -0.27 |
| Stochastic Oscillator | 95.53 | 17.38 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States, and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.